Results 111 to 120 of about 31,068 (241)
Vitreous Hemorrhage in Pediatric Age Group
Purpose. To identify and study causes of vitreous hemorrhage (VH) in pediatric age group and to investigate factors predicting visual and anatomical outcomes. Procedure.
Dora H. AlHarkan +3 more
doaj +1 more source
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang +3 more
wiley +1 more source
Tuberculous Endophthalmitis With Phthisis Bulbi: A Diagnostic Delay Case Report
ABSTRACT Tuberculous endophthalmitis should be prioritized in differential diagnosis for unexplained endophthalmitis in TB‐endemic regions; early systemic evaluation, timely pars plana vitrectomy, and adjunctive corticosteroids are crucial to prevent phthisis bulbi, though evidence for some interventions remains limited.
Yanchen Chen +4 more
wiley +1 more source
A Cationic Block Co‐Polymer for Gene Delivery in the Posterior Segment of the Eye
ABSTRACT Diseases of the back of the eye such as neovascular age‐related macular degeneration (nAMD) are vision threatening and treatment is burdensome for patients, often requiring ocular injections every other month. Injection risks and logistics lower patient compliance; however, even patients receiving optimal treatment can deteriorate.
Amber Monteiro +8 more
wiley +1 more source
A Bruchs membrane (BrM) mimic based on aged decellularized BrM was developed and differentially expressed proteins in aged dECM‐BrM that may provide specific biochemical cues fundamental to model AMD in vitro were identified. RPE culture on aged dECM‐BrM developed certain AMD‐like features including reduced TEER and expression of drusen components ...
Blanca Molins +8 more
wiley +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source
Vascular changes in diabetic retinopathy-a longitudinal study in the Nile rat. [PDF]
Diabetic retinopathy is the most common microvascular complication of diabetes and is a major cause of blindness, but an understanding of the pathogenesis of the disease has been hampered by a lack of accurate animal models. Here, we explore the dynamics
Blodi, Barbara A +10 more
core
Optimizing Oligonucleotide Therapeutics: A Model‐Informed Drug Development Perspective
ABSTRACT Oligonucleotide therapies have emerged as a powerful therapeutic class, providing novel solutions for diverse diseases through antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers that specifically target and modulate gene expression or protein function. However, oligonucleotide development faces distinct challenges,
Ye Yuan +7 more
wiley +1 more source
ABSTRACT Aims/Introduction This study aimed to clarify the relationship between glucose metrics measured by continuous glucose monitoring (CGM) and diabetic retinopathy (DR) and albuminuria among Japanese individuals with type 1 diabetes mellitus. Materials and Methods The study included 294 individuals with type 1 diabetes (68.7% women) who underwent ...
Yuichiro Kondo +8 more
wiley +1 more source
ABSTRACT Objective To describe the clinical outcome of intravitreal cidofovir injection for palliative management of refractory end‐stage glaucoma and vision loss in silicone oil‐filled eyes following retinal reattachment surgery in dogs. Procedures Medical records of dogs that underwent a single intravitreal cidofovir injection for pharmacologic ...
Sunhyo Kim, Jaeho Shim
wiley +1 more source

